These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

356 related items for PubMed ID: 17334518

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. A novel synthetic inhibitor of factor Xa decreases early reocclusion and improves 24-h patency after coronary fibrinolysis in dogs.
    Abendschein DR, Baum PK, Verhallen P, Eisenberg PR, Sullivan ME, Light DR.
    J Pharmacol Exp Ther; 2001 Feb; 296(2):567-72. PubMed ID: 11160645
    [Abstract] [Full Text] [Related]

  • 3. Direct and rapid inhibition of factor Xa by otamixaban: a pharmacokinetic and pharmacodynamic investigation in patients with coronary artery disease.
    Hinder M, Frick A, Jordaan P, Hesse G, Gebauer A, Maas J, Paccaly A.
    Clin Pharmacol Ther; 2006 Dec; 80(6):691-702. PubMed ID: 17178269
    [Abstract] [Full Text] [Related]

  • 4. Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome.
    Becker RC, Alexander JH, Newby LK, Yang H, Barrett Y, Mohan P, Wang J, Harrington RA, Wallentin LC.
    Thromb Haemost; 2010 Nov; 104(5):976-83. PubMed ID: 20806117
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Pharmacodynamic markers in the early clinical assessment of otamixaban, a direct factor Xa inhibitor.
    Paccaly A, Ozoux ML, Chu V, Simcox K, Marks V, Freyburger G, Sibille M, Shukla U.
    Thromb Haemost; 2005 Dec; 94(6):1156-63. PubMed ID: 16411387
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Xa inhibition and coagulation activity--the influence of prolonged dalteparin treatment and gender in patients with acute coronary syndrome and healthy individuals.
    Oldgren J, Johnston N, Siegbahn A.
    Am Heart J; 2008 Mar; 155(3):493.e1-8. PubMed ID: 18294482
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Arterial antithrombotic activity of rivaroxaban, an orally active factor Xa inhibitor, in a rat electrolytic carotid artery injury model of thrombosis.
    Parry TJ, Huang Z, Chen C, Connelly MA, Perzborn E, Andrade-Gordon P, Damiano BP.
    Blood Coagul Fibrinolysis; 2011 Dec; 22(8):720-6. PubMed ID: 21986468
    [Abstract] [Full Text] [Related]

  • 13. A thromboxane A2/prostaglandin H2 receptor antagonist (S18886) shows high antithrombotic efficacy in an experimental model of stent-induced thrombosis.
    Vilahur G, Casaní L, Badimon L.
    Thromb Haemost; 2007 Sep; 98(3):662-9. PubMed ID: 17849057
    [Abstract] [Full Text] [Related]

  • 14. Is the inhibition of both clot-associated thrombin and factor Xa more clinically relevant than either one alone?
    Meddahi S, Samama MM.
    Blood Coagul Fibrinolysis; 2009 Apr; 20(3):207-14. PubMed ID: 19657318
    [Abstract] [Full Text] [Related]

  • 15. Evaluation of AR-H067637, the active metabolite of the new direct thrombin inhibitor AZD0837, in models of venous and arterial thrombosis and bleeding in anaesthetised rats.
    Pehrsson S, Johansson K, Kjaer M, Elg M.
    Thromb Haemost; 2010 Dec; 104(6):1242-9. PubMed ID: 20806126
    [Abstract] [Full Text] [Related]

  • 16. Antithrombotic and anticoagulant profiles of TAK-442, a novel factor Xa inhibitor, in a rabbit model of venous thrombosis.
    Kawamura M, Konishi N, Hiroe K, Shofuda K, Imaeda Y, Fujimoto T, Kubo K.
    J Cardiovasc Pharmacol; 2010 Aug; 56(2):156-61. PubMed ID: 20410831
    [Abstract] [Full Text] [Related]

  • 17. Monitoring high-dose heparinization during cardiopulmonary by-pass--a comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays.
    Raivio P, Kuitunen A, Petäjä J, Ilveskero S, Lassila R.
    Thromb Haemost; 2008 Feb; 99(2):427-34. PubMed ID: 18278195
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor.
    Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G.
    Clin Pharmacol Ther; 2005 Oct; 78(4):412-21. PubMed ID: 16198660
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.